Key statistics dashboard for Quoin Pharmaceuticals, Ltd. (QNRX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment.
Stock Data
| Price | $6.90 |
| Market Cap | $14M |
| Enterprise Value | $10.0M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.46 |
| Price / Book | 3.48 |
| P/S | 0.00 |
| EV/EBITDA | -0.53 |
| EV/Sales | 0.00 |
| EV/FCF | -0.65 |
| P/FCF | -0.89 |
| Earnings Yield | -135.35% |
| FCF Yield | -111.06% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -304.87% |
| Return on Assets | -156.71% |
| Return on Invested Capital | -359.18% |
| Return on Capital Employed | -359.18% |
Financial Health
| Current Ratio | 1.76 |
| Quick Ratio | 1.76 |
| Cash Ratio | 0.58 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Net Debt / EBITDA | 0.20 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 1.96 |
| Cash per share | 5.38 |
| FCF per share | -7.66 |
| Tangible Book Value per share | 1.79 |
| Dividend per share | 0.00 |
Related companies: CYCN · KTTA · NBY · PLRZ · PMCB · RADX · TCRT
Explore sector: Healthcare · Biotechnology
More sections of QNRX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks